Hematological Malignancies | Norton Healthcare

Indication: Hematological Malignancies

Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Comparing the Efficacy and Safety of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Alone Versu

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Email for more information: Heme-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.